Adiponectin may mediate the association between omentin, circulating lipids and insulin sensitivity: Results from the KORA F4 study

European Journal of Endocrinology

Volumn 172, Issue 4, 2015, Pages 423-432

  Herder, Christian ^a,b   Ouwens, D Margriet ^a,b,c   Carstensen, Maren ^a,b   Kowall, Bernd ^a,b   Huth, Cornelia ^d,e   Meisinger, Christa ^d,e   Rathmann, Wolfgang ^a,b   Roden, Michael ^a,b,f   Thorand, Barbara ^d,e  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b LEIBNIZ CENTER FOR DIABETES RESEARCH AT HEINRICH HEINE UNIVERSITY DÜSSELDORF   (Germany)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^f UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; OMENTIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ADIPOQ PROTEIN, HUMAN; CYTOKINE; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; ITLN1 PROTEIN, HUMAN; LECTIN;

ADULT; AGE; AGED; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENDER; GERMANY; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE TOLERANCE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; LIFESTYLE; LIPID BLOOD LEVEL; LIPID METABOLISM; MALE; ORAL GLUCOSE TOLERANCE TEST; POPULATION RESEARCH; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; DIABETES MELLITUS, TYPE 2; GLUCOSE INTOLERANCE; INSULIN RESISTANCE; MIDDLE AGED; OBESITY; PHYSIOLOGY; RISK FACTOR;

ADIPONECTIN; AGED; CROSS-SECTIONAL STUDIES; CYTOKINES; DIABETES MELLITUS, TYPE 2; FEMALE; GERMANY; GLUCOSE INTOLERANCE; GPI-LINKED PROTEINS; HUMANS; INSULIN RESISTANCE; LECTINS; LIPIDS; MALE; MIDDLE AGED; OBESITY; RISK FACTORS;

EID: 84927586650     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-14-0879     Document Type: Article

References (34)

1. Herder C, Carstensen M & Ouwens DM. Anti-inflammatory cytokines and risk of type 2 diabetes. Diabetes, Obesity & Metabolism 2013 15 (Suppl 3) 39-50. (doi:10.1111/dom.12155)
2. Carstensen M, Herder C, Kivimaki M, Jokela M, Roden M, Shipley MJ, Witte DR, Brunner EJ & Tabak AG. Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes 2010 59 1222-1227. (doi:10.2337/db09-1199)
3. Herder C, Brunner EJ, Rathmann W, Strassburger K, Tabak AG, Schloot NC & Witte DR. Elevated levels of the anti-inflammatory interleukin-1 receptor antagonist precede the onset of type 2 diabetes: the Whitehall II study. Diabetes Care 2009 32 421-423. (doi:10.2337/dc08-1161)
4. Luotola K, Pietila A, Zeller T, Moilanen L, Kahonen M, Nieminen MS, Kesaniemi YA, Blankenberg S, Jula A, Perola M et al. Associations between interleukin-1 (IL-1) gene variations or IL-1 receptor antagonist levels and the development of type 2 diabetes. Journal of Internal Medicine 2011 269 322-332. (doi:10.1111/j.1365-2796.2010.02294.x)
5. Salomaa V, Havulinna A, Saarela O, Zeller T, Jousilahti P, Jula A, Muenzel T, Aromaa A, Evans A, Kuulasmaa K et al. Thirty-one novel biomarkers as predictors for clinically incident diabetes. PLoS ONE 2010 5 e10100. (doi:10.1371/journal.pone.0010100)
6. Li S, Shin HJ, Ding EL & van Dam RM. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. Journal of the American Medical Association 2009 302 179-188. (doi:10.1001/jama.2009.976)
7. de Souza Batista CM, Yang RZ, Lee MJ, Glynn NM, Yu DZ, Pray J, Ndubuizu K, Patil S, Schwartz A, Kligman M et al. Omentin plasma levels and gene expression are decreased in obesity. Diabetes 2007 56 1655-1661. (doi:10.2337/db06-1506)
8. Yan P, Liu D, Long M, Ren Y, Pang J & Li R. Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus. Experimental and Clinical Endocrinology & Diabetes 2011 119 257-263. (doi:10.1055/s-0030-1269912)
9. Yang RZ, Lee MJ, Hu H, Pray J, Wu HB, Hansen BC, Shuldiner AR, Fried SK, McLenithan JC & Gong DW. Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action. American Journal of Physiology. Endocrinology and Metabolism 2006 290 E1253-E1261. (doi:10.1152/ajpendo.00572.2004)
10. Tan BK, Adya R & Randeva HS. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends in Cardiovascular Medicine 2010 20 143-148. (doi:10.1016/j.tcm.2010.12.002)
11. Catli G, Anik A, Abaci A, Kume T & Bober E. Low omentin-1 levels are related with clinical and metabolic parameters in obese children. Experimental and Clinical Endocrinology & Diabetes 2013 121 595-600. (doi:10.1055/s-0033-1355338)
12. Pan HY, Guo L & Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. Diabetes Research and Clinical Practice 2010 88 29-33. (doi:10.1016/j.diabres.2010.01.013)
13. Saremi A, Asghari M & Ghorbani A. Effects of aerobic training on serum omentin-1 and cardiometabolic risk factors in overweight and obese men. Journal of Sports Sciences 2010 28 993-998. (doi:10.1080/02640414.2010.484070)
14. Wang Q, Feng X, Zhou C, Li P & Kang J. Decreased levels of serum omentin-1 in patients with obstructive sleep apnoea syndrome. Annals of Clinical Biochemistry 2013 50 230-235. (doi:10.1177/0004563212473275)
15. Greulich S, Chen WJ, Maxhera B, Rijzewijk LJ, van der Meer RW, Jonker JT, Mueller H, de Wiza DH, Floerke RR, Smiris K et al. Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies. PLoS ONE 2013 8 e59697. (doi:10.1371/journal.pone.0059697)
16. Onur I, Oz F, Yildiz S, Oflaz H, Sigirci S, Elitok A, Pilten S, Karaayvaz EB, Cizgici AY, Kaya MG et al. Serum omentin 1 level is associated with coronary artery disease and its severity in postmenopausal women. Angiology 2014 65 896-900. (doi:10.1177/0003319713511322)
17. Kazama K, Usui T, Okada M, Hara Y & Yamawaki H. Omentin plays an anti-inflammatory role through inhibition of TNF-α-induced super-oxide production in vascular smooth muscle cells. European Journal of Pharmacology 2012 686 116-123. (doi:10.1016/j.ejphar.2012.04.033)
18. Yamawaki H, Kuramoto J, Kameshima S, Usui T, Okada M & Hara Y. Omentin, a novel adipocytokine inhibits TNF-induced vascular inflammation in human endothelial cells. Biochemical and Biophysical Research Communications 2011 408 339-343. (doi:10.1016/j.bbrc.2011.04.039)
19. Zhong X, Li X, Liu F, Tan H & Shang D. Omentin inhibits TNF-α-induced expression of adhesion molecules in endothelial cells via ERK/NF-κB pathway. Biochemical and Biophysical Research Communications 2012 425 401-406. (doi:10.1016/j.bbrc.2012.07.110)
20. Rathmann W, Strassburger K, Heier M, Holle R, Thorand B, Giani G & Meisinger C. Incidence of type 2 diabetes in the elderly German population and the effect of clinical and lifestyle risk factors: KORA S4/F4 cohort study. Diabetic Medicine 2009 26 1212-1219. (doi:10.1111/j.1464-5491.2009.02863.x)
21. Rathmann W, Haastert B, Icks A, Lowel H, Meisinger C, Holle R & Giani G. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 2003 46 182-189. (doi:10.1007/s00125-002-1025-0)
22. World Health Organisation. Report of a WHO Consultation: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Geneva: World health Organization, 1999.
23. DeFronzo RA & Matsuda M. Reduced time points to calculate the composite index. Diabetes Care 2010 33 e93. (doi:10.2337/dc10-0646)
24. Levey AS, Cattran D, Friedman A, Miller WG, Sedor J, Tuttle K, Kasiske B & Hostetter T. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. American Journal of Kidney Diseases 2009 54 205-226. (doi:10.1053/j.ajkd.2009.04.029)
25. Herder C, Bongaerts BW, Rathmann W, Heier M, Kowall B, Koenig W, Thorand B, Roden M, Meisinger C & Ziegler D. Association of subclinical inflammation with polyneuropathy in the older population: KORA F4 study. Diabetes Care 2013 36 3663-3670. (doi:10.2337/dc13-0382)
26. Jialal I, Devaraj S, Kaur H, Adams-Huet B & Bremer AA. Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. Journal of Clinical Endocrinology and Metabolism 2013 98 E514-E517. (doi:10.1210/jc.2012-3673)
27. Orlik B, Madej P, Owczarek A, Skalba P, Chudek J & Olszanecka-Glinianowicz M. Plasma omentin and adiponectin levels as markers of adipose tissue dysfunction in normal weight and obese women with polycystic ovary syndrome. Clinical Endocrinology 2014 81 529-535. (doi:10.1111/cen.12381)
28. Vu A, Sidhom MS, Bredbeck BC, Kosmiski LA & Aquilante CL. Evaluation of the relationship between circulating omentin-1 concentrations and components of the metabolic syndrome in adults without type 2 diabetes or cardiovascular disease. Diabetology & Metabolic Syndrome 2014 6 4. (doi:10.1186/1758-5996-6-4)
29. Moreno-Navarrete JM, Catalan V, Ortega F, Gomez-Ambrosi J, Ricart W, Fruhbeck G & Fernandez-Real JM. Circulating omentin concentration increases after weight loss. Nutrition & Metabolism 2010 7 27. (doi:10.1186/1743-7075-7-27)
30. Siejka A, Jankiewicz-Wika J, Kolomecki K, Cywinski J, Piestrzeniewicz K, Swietoslawski J, Stepien H & Komorowski J. Long-term impact of vertical banded gastroplasty (VBG) on plasma concentration of leptin, soluble leptin receptor, ghrelin, omentin-1, obestatin, and retinol binding protein 4 (RBP4) in patients with severe obesity. Cytokine 2013 64 490-493. (doi:10.1016/j.cyto.2013.07.026)
31. Wang XH, Dou LZ, Gu C & Wang XQ. Plasma levels of omentin-1 and visfatin in senile patients with coronary heart disease and heart failure. Asian Pacific Journal of Tropical Medicine 2014 7 55-62. (doi:10.1016/S1995-7645(13)60192-3)
32. Akiyama Y, Oshima K, Kuhara T, Shin K, Abe F, Iwatsuki K, Nadano D & Matsuda T. A lactoferrin-receptor, intelectin 1, affects uptake, subcellular localization and release of immunochemically detectable lactoferrin by intestinal epithelial Caco-2 cells. Journal of Biochemistry 2013 154 437-448. (doi:10.1093/jb/mvt073)
33. Moreno-Navarrete JM, Ortega FJ, Bassols J, Ricart W & Fernandez-Real JM. Decreased circulating lactoferrin in insulin resistance and altered glucose tolerance as a possible marker of neutrophil dysfunction in type 2 diabetes. Journal of Clinical Endocrinology and Metabolism 2009 94 4036-4044. (doi:10.1210/jc.2009-0215)
34. Holland WL, Adams AC, Brozinick JT, Bui HH, Miyauchi Y, Kusminski CM, Bauer SM, Wade M, Singhal E, Cheng CC et al. An FGF21-adiponectin-ceramide axis controls energy expenditure and insulin action in mice. Cell Metabolism 2013 17 790-797. (doi:10.1016/j.cmet.2013.03.019)